Golimumab (Immgolis INTRI®, Simponi ARIA®) — Intravenous
Customize your policy alerts
Sign up for Viva Health Policy IC-0176 alerts
Get alerted when Policy IC-0176 changes without checking for updates manually.
Monitor payer policy activity
Coverage and prior authorization requirements for intravenous golimumab (Immgolis INTRI®, Simponi ARIA®) for indicated immune-mediated rheumatologic conditions and immune checkpoint inhibitor-related toxicities for Viva Health members.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.